29. Atopic Dermatitis: Scoring Severity and Quality of Life Assessment

  1. Alan D. Irvine MD, FRCPI, FRCP3,4,
  2. Peter H. Hoeger MD5,6 and
  3. Albert C. Yan MD, FAAP, FAAD7,8
  1. M. Susan Lewis-Jones MBChB, FRCP, FRCPCH1 and
  2. Carolyn R. Charman BMBCH, MD, FRCP2

Published Online: 24 MAY 2011

DOI: 10.1002/9781444345384.ch29

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

How to Cite

Lewis-Jones, M. S. and Charman, C. R. (2011) Atopic Dermatitis: Scoring Severity and Quality of Life Assessment, in Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition (eds A. D. Irvine, P. H. Hoeger and A. C. Yan), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444345384.ch29

Editor Information

  1. 3

    Trinity College, Dublin, Ireland

  2. 4

    Our Lady's Children's Hospital, Dublin, Ireland

  3. 5

    University of Hamburg, Hamburg, Germany

  4. 6

    Catholic Children's Hospital Wilhelmstift, Hamburg, Germany

  5. 7

    University of Pennsylvania School of Medicine, Philadelphia, PA, USA

  6. 8

    The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Author Information

  1. 1

    Department of Dermatology, Ninewells Hospital and Medical School, Dundee, Scotland, UK

  2. 2

    Department of Dermatology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

Publication History

  1. Published Online: 24 MAY 2011
  2. Published Print: 3 JUN 2011

ISBN Information

Print ISBN: 9781405176958

Online ISBN: 9781444345384

SEARCH

Keywords:

  • atopic;
  • dermatitis;
  • SCORAD;
  • scoring;
  • severity;
  • quality of life

Summary

To provide a comprehensive assessment of atopic dermatitis severity, it is important to measure a combination of parameters: objective visual skin changes (clinical signs), patient symptoms and quality of life, as all three measures provide different information about disease severity. Of the numerous objective severity scales described for atopic dermatitis, the SCORAD index and Eczema Area and Severity Index have been most extensively validated and widely used. For measuring disease severity from the patient's perspective, the Patient Oriented Eczema Measure or visual analogue scores of itch and sleep loss should be employed. In future, more emphasis should be placed on measuring the impact of changes in atopic dermatitis severity on quality of life, using validated measures such as the Children's Dermatology Life Quality Index, Infants' Dermatitis Quality of Life index or Dermatitis Family Impact questionnaire.